NASDAQ:CTIC

CTI BioPharma Stock Forecast, Price & News

$2.31
-0.09 (-3.75 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.30
$2.43
50-Day Range
$2.16
$2.54
52-Week Range
$0.96
$4.13
Volume915,291 shs
Average Volume872,903 shs
Market Capitalization$215.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
30 days | 90 days | 365 days | Advanced Chart
Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.


CTI BioPharma logo

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

202nd out of 2,097 stocks

Pharmaceutical Preparations Industry

93rd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

Is CTI BioPharma a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTI BioPharma stock.
View analyst ratings for CTI BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than CTI BioPharma?

Wall Street analysts have given CTI BioPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CTI BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 2,120,000 shares, an increase of 24.7% from the May 13th total of 1,700,000 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is currently 2.0 days. Currently, 2.5% of the shares of the stock are sold short.
View CTI BioPharma's Short Interest
.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for CTI BioPharma
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings data on Tuesday, June, 1st. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.01. During the same quarter last year, the company posted ($0.19) EPS.
View CTI BioPharma's earnings history
.

How has CTI BioPharma's stock price been impacted by Coronavirus?

CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CTIC shares have increased by 159.5% and is now trading at $2.31.
View which stocks have been most impacted by COVID-19
.

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CTIC?

5 equities research analysts have issued 1-year price targets for CTI BioPharma's stock. Their forecasts range from $3.00 to $15.00. On average, they expect CTI BioPharma's share price to reach $7.30 in the next twelve months. This suggests a possible upside of 216.0% from the stock's current price.
View analysts' price targets for CTI BioPharma
or view top-rated stocks among Wall Street analysts.

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the following people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 55, Pay $1.03M)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 67, Pay $511.74k)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 57, Pay $598k)
  • Mr. Ed Bell, Sr. Director of Investor Relations
  • Mr. Jim Fong, Sr. VP of Global Operations
  • Mr. Bruce K. Bennett Jr., Sr. VP Global Pharmaceutical Operations (Age 69)
  • Mr. John Volpone, Sr. VP of Strategic Operations
  • Dr. Jennifer A. Smith, Sr. VP of Biometrics

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma CEO James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among CTI BioPharma's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (8.06%), Renaissance Technologies LLC (1.73%), Morgan Stanley (1.57%), Verition Fund Management LLC (1.19%), BlackRock Inc. (1.00%) and Geode Capital Management LLC (0.52%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il and Orbimed Advisors Llc.
View institutional ownership trends for CTI BioPharma
.

Which major investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Renaissance Technologies LLC, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for CTI BioPharma
or view top insider-selling stocks.

Which major investors are buying CTI BioPharma stock?

CTIC stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Verition Fund Management LLC, Barclays PLC, HRT Financial LP, Millennium Management LLC, Geode Capital Management LLC, and Occudo Quantitative Strategies LP.
View insider buying and selling activity for CTI BioPharma
or or view top insider-buying stocks.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $2.31.

How much money does CTI BioPharma make?

CTI BioPharma has a market capitalization of $215.48 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-52,450,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does CTI BioPharma have?

CTI BioPharma employs 22 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is www.ctibiopharma.com.

Where are CTI BioPharma's headquarters?

CTI BioPharma is headquartered at 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.